Arno Therapeutics to Collaborate With Veridex on Development of Diagnostic Test
June 03 2013 - 8:00AM
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage
biopharmaceutical company focused on the development of oncology
therapeutics, today announced that it has signed an agreement with
Veridex, LLC, a Johnson & Johnson company, to develop a
diagnostic test to detect the presence of activated progesterone
receptors (APRs) as a potential biomarker of anti-progestin
activity in circulating tumor cells (CTCs). The diagnostic will
help identify patients whom could potentially benefit from
treatment with anti-progestins including onapristone, an
orally-administered, investigational type 1 progestin receptor
antagonist being developed by Arno.
CTCs are cancer cells that have detached from a solid tumor in
the body and are found in the bloodstream. The collaboration
will allow Arno to utilize Veridex's proprietary technology,
CELLSEARCH®, which uses an advanced cell separation technique
called microfluidic separation integrated with innovative magnetic
sorting, to isolate CTCs and further analyze the cells for the
presence of APR. The CELLSEARCH® CTC System is the first and
only standardized, FDA-cleared, semi-automated system that
captures, isolates, and counts CTCs with a high level of
sensitivity and specificity.
In pre-clinical studies, the presence of APR has shown to be
predictive of onapristone activity. Onapristone is believed to
work by binding to progesterone receptor proteins, thereby
inhibiting dimerization, phosphorylation and DNA transcription
activity. Progesterone receptors (PRs) are found in particular
cells including those of the female reproductive tissue and some
cancers.i The hormone progesterone binds to the receptors and may
cause the cells to grow.i Preclinical studies have shown that PRs
can play a role as drivers of malignant cell growth in certain
cancers.
"We are pleased to work with Veridex as we believe its
pioneering technology for isolating circulating tumor cells will
serve as an important tool for the continued development and study
of onapristone," said Glenn Mattes, chief executive officer and
president, Arno Therapeutics. "By taking blood samples from
patients rather than obtaining tissue samples, we hope to create a
simplified and less invasive process for identifying patients that
are most likely to benefit from treatment with onapristone."
The diagnostic test will be used in future clinical studies of
onapristone, which the company is planning to begin in the second
half of 2013.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company
developing innovative products for the treatment of
cancer. Arno has exclusive worldwide rights to develop and
market three innovative anti-cancer product candidates. These
compounds are in clinical or preclinical development as product
candidates to treat hematologic malignancies and solid
tumors. For more information about the company, please
visit www.arnothera.com.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. These statements are
often, but not always, made through the use of words or phrases
such as "anticipates," "expects," "plans," "believes," "intends,"
and similar words or phrases. These forward-looking statements
include, without limitation, statements regarding the timing,
progress and anticipated results of the clinical development of
onapristone, Arno's use of the diagnostic test being developed with
Veridex in its planned Phase I trial of onapristone, as well as
Arno's strategy, future operations, outlook, milestones, future
financial position, future financial results, plans and objectives.
We may not actually achieve these plans, intentions or expectations
and Arno cautions investors not to place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements we make. Various important factors
could cause actual results or events to differ materially from the
forward-looking statements that we make. Such factors include,
among others, risks that the results of clinical trials will not
support our claims or beliefs concerning the effectiveness of
onapristone or any of our other product candidates, our ability to
finance the development of our product candidates, regulatory
risks, and our reliance on third party researchers and other
collaborators. Additional risks are described in the company's
Annual Report on Form 10-K for the year ended December 31, 2012.
Arno is providing this information as of the date of this press
release and does not undertake any obligation to update any
forward-looking statements as a result of new information, future
events or otherwise.
i National Cancer Institute. NCI Dictionary of
Cancer Terms. Available at:
http://www.cancer.gov/dictionary?cdrid=423248. Last accessed: May
7, 2013.
CONTACT: The Ruth Group
Stephanie Carrington (investors)
scarrington@theruthgroup.com
(646) 536-7017
Caitlin Cox (media)
ccox@theruthgroup.com
(646) 536-7033
Arno Therapeutics
Glenn Mattes
gm@arnothera.com
(862) 703-7176
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024